Targeting the Jak/STAT pathway for immunosuppression.
O'shea
J J
JJ
Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA. osheajo@mail.nih.gov
D000818:Animals; D016207:Cytokines / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D053616:Janus Kinase 3; D051379:Mice; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D016511:Severe Combined Immunodeficiency / Q000276:immunology; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology; D015534:Trans-Activators / Q000037:antagonists & inhibitors*
D016207:Cytokines; D007166:Immunosuppressive Agents; D015534:Trans-Activators; D011505:Protein-Tyrosine Kinases; C507933:JAK3 protein, human; C507935:Jak3 protein, mouse; D053616:Janus Kinase 3